Sumithra S, Shanmugasundaram P, Ravichandiran V. Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS. Hang TJ, Zhang M, Song M, Shen JP, Zhang YD. In vitro release kinetic study of ambroxol hydrochloride sustained release matrix tablets using hydrophilic and hydrophobic polymers.
Int Res J Pharm 2014 5:580-3.Īkhter DT, Uddin R, Sutradhar KB, Rana S. Development and validation for UV Spectrometric estimation of ambroxol hydrochloride in bulk and tablet dosage form using the area under the curve method. In vitro characterization and release study of ambroxol hydrochloride matrix tablets prepared by direct compression. Int J Pharm Pharm Sci 2011 13 Suppl 3:2003.Ībd Elbary A, Haider M, Sayed S. Design and development of ambroxol hydrochloride sustained release matrix tablets. A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough. Hull University Teaching Hospitals NHS Trust. Formulation and release behavior of sustained-release ambroxol hydrochloride HPMC matrix tablet. Simultaneous estimation of ambroxol hydrochloride and cetirizine hydrochloride in pharmaceutical tablet dosage form by simultaneous equation spectrophotometric method: a quality control tool for dissolution studies. Jaysukh J, Hirani JJ, Rathod DA, Vadalia KR. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution, and bioavailability. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. A review of disintegration mechanisms and measurement techniques. The dissolution test results showed that in the 45-minute test each percent dissolved concentration of the active substance for F1, F2, F3, and F4 was 58.77974, 66.91104, 80.09946, and 64.02293 suggesting only the F3 formula fulfilled the dissolution requirements according to European Pharmacopoeia which stated that the concentration of dissolved active tablets should not be less than 75% during the 45-minute test.Ĭonclusion: The formula that met the solubility requirements consisted of an additional 69% Ludipress® and 10% lactose with a solubility value of 80.09%. All four formulas meet the Indonesian pharmacopeia requirements for time of violence, fragility and disintegration. The results of evaluation tablets, which included uniformity of weight, uniformity of size, hardness, friability, disintegration time, and dissolution test, were found that only F1 formula did not meet uniformity requirements.
Results: From the results of the Mass Printing Evaluation of Tablets, it was found that the four formulas that were designed met the resting angle, flow rate, real density, compressed density, and compressibility met existing requirements. Data obtained in the analysis using the perfect random block design method (DBAS) with α = 0.05 where blocks and groups were used. The tablet was then evaluated, which includes uniformity in weight, diameter, thickness, hardness, friability, disintegration time, and dissolution. For research purposes, 4 formulas with variations of Ludipress® and Lactose were designed. Methods: Ambroxol HCl tablets were made by direct pressing method. The aim of this study was to obtain a comparative composition of Ludipress® and lactose additives suitable for producing ambroxol HCl tablets that met the ambroxol acceleration ambroxol in the body. Additional substances contained in pharmaceutical preparations, one of which serves to accelerate the solubility of active substances. The process of dissolving drugs is called dissolution. Objective: The drug will provide a therapeutic effect when dissolved so that it is easily absorbed. Faculty of Pharmacy, Universitas Padjadjaran, Hegarmanah, Jatinangor, Jawa Barat 45363, Indonesiaĭissolution profile, Ambroxol HCl tablets, Direct press, Nil, Lactose Abstract
0 kommentar(er)
